IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Shares Sold by Fiera Capital Corp

Fiera Capital Corp trimmed its position in shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA) by 8.2% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,184,467 shares of the company’s stock after selling 105,353 shares during the period. Fiera Capital Corp owned 1.37% of IDEAYA Biosciences worth $30,441,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of the company. State Street Corp boosted its position in shares of IDEAYA Biosciences by 15.4% during the third quarter. State Street Corp now owns 3,317,936 shares of the company’s stock worth $105,112,000 after buying an additional 443,640 shares during the period. Barclays PLC raised its stake in IDEAYA Biosciences by 188.8% during the 3rd quarter. Barclays PLC now owns 181,170 shares of the company’s stock valued at $5,739,000 after acquiring an additional 118,438 shares in the last quarter. Charles Schwab Investment Management Inc. grew its stake in shares of IDEAYA Biosciences by 12.9% in the third quarter. Charles Schwab Investment Management Inc. now owns 689,073 shares of the company’s stock worth $21,830,000 after purchasing an additional 78,518 shares in the last quarter. Verition Fund Management LLC acquired a new position in shares of IDEAYA Biosciences during the third quarter valued at $246,000. Finally, General American Investors Co. Inc. acquired a new position in shares of IDEAYA Biosciences during the third quarter valued at $2,851,000. Institutional investors own 98.29% of the company’s stock.

Analyst Ratings Changes

Several research firms recently weighed in on IDYA. Leerink Partners downgraded shares of IDEAYA Biosciences from an “outperform” rating to a “market perform” rating and reduced their price objective for the stock from $41.00 to $27.00 in a report on Tuesday, November 5th. Oppenheimer reiterated an “outperform” rating and issued a $53.00 target price on shares of IDEAYA Biosciences in a report on Tuesday, October 29th. UBS Group began coverage on shares of IDEAYA Biosciences in a research note on Thursday, October 24th. They set a “buy” rating and a $50.00 target price on the stock. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $61.00 target price on shares of IDEAYA Biosciences in a research report on Wednesday, January 15th. Finally, Stephens started coverage on IDEAYA Biosciences in a report on Monday, November 18th. They set an “overweight” rating and a $51.00 price target on the stock. Two investment analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $53.67.

IDEAYA Biosciences Price Performance

IDEAYA Biosciences stock opened at $20.76 on Friday. IDEAYA Biosciences, Inc. has a one year low of $20.66 and a one year high of $47.74. The company’s fifty day moving average price is $24.60 and its two-hundred day moving average price is $30.18. The company has a market capitalization of $1.79 billion, a price-to-earnings ratio of -8.91 and a beta of 0.82.

IDEAYA Biosciences (NASDAQ:IDYA) last issued its quarterly earnings data on Tuesday, February 18th. The company reported ($1.49) EPS for the quarter, missing analysts’ consensus estimates of ($0.63) by ($0.86). As a group, sell-side analysts anticipate that IDEAYA Biosciences, Inc. will post -2.45 earnings per share for the current year.

IDEAYA Biosciences Profile

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.